Annette Clancy

Chairman at SWEDISH ORPHAN BIOVITRUM AB

Net worth: 90 719 $ as of 2024-03-30

70 year

100 connections

Health Technology

Commercial Services

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Jacky Vonderscher	M	69	OBSEVA SA ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	11 years
Per Richard Torbjörn Hallberg	M	55	SWEDISH ORPHAN BIOVITRUM AB	6 years
Benoit de Chassey	M	-	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	10 years
Timothy M. Wright	M	69	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	-
Carole Deffez	F	-	LYSOGENE	5 years
Armin Reininger	M	67	SWEDISH ORPHAN BIOVITRUM AB	7 years
Filippa Stenberg	F	-	SWEDISH ORPHAN BIOVITRUM AB	-
Helena Ildiko Saxon	F	54	SWEDISH ORPHAN BIOVITRUM AB	13 years
Vincent Lotteau	M	-	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	10 years
Staffan Schüberg	M	55	SWEDISH ORPHAN BIOVITRUM AB	4 years
Jean-Jacques Garaud	M	68	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	10 years
Peter Lichtlen	M	56	LYSOGENE	6 years
Guido Oelkers	M	59	SWEDISH ORPHAN BIOVITRUM AB	7 years
Patrice André	M	-	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	10 years
Laurène Meyniel-Schickl	F	-	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	10 years
Sven Ullman	M	68	SWEDISH ORPHAN BIOVITRUM AB	3 years
James Ford	M	-	GSK PLC	29 years
Norbert Oppitz	M	57	SWEDISH ORPHAN BIOVITRUM AB	7 years
Henrik Stenqvist	M	57	SWEDISH ORPHAN BIOVITRUM AB	6 years
Mahmood Ladha	M	60	SWEDISH ORPHAN BIOVITRUM AB	5 years
Pablo de Mora	M	56	SWEDISH ORPHAN BIOVITRUM AB	5 years
Christine Wesström	F	49	SWEDISH ORPHAN BIOVITRUM AB	14 years
Lydia Abad-Franch	M	-	SWEDISH ORPHAN BIOVITRUM AB	-
Daniel Rankin	M	44	SWEDISH ORPHAN BIOVITRUM AB	7 years
Ralph Laufer	M	-	LYSOGENE	6 years
Jason Robert Dinges	M	48	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	-
Laurent Arthaud	M	61	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	4 years
Lena Bjurner	F	56	SWEDISH ORPHAN BIOVITRUM AB	1 years
Laurent Higueret	M	-	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	-
Eric Meldrum	M	-	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	-
David Redfern	M	57	GSK PLC	30 years
Maina Bhaman	M	52	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	-
Iain Dukes	M	65	ENYO Pharma SA ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.	6 years
Graham Rivers	M	-	GSK PLC	26 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Bo Jesper Hansen	M	66	SWEDISH ORPHAN BIOVITRUM AB	9 years
Martin Nes	M	55	WEIFA ASA	-
Frank Verwiel	M	62	OBSEVA SA	6 years
Rafaèle Elisabeth Tordjman	M	54	LYSOGENE OBSEVA SA	8 years
Wills Hughes-Wilson	F	53	SWEDISH ORPHAN BIOVITRUM AB	6 years
Ahmad Mortazavi	M	53	SILENCE THERAPEUTICS PLC	6 years
Fabien de Ladonchamps	M	45	OBSEVA SA	9 years
Moncef Slaoui	M	64	GSK PLC	11 years
Katja Buhrer	F	-	OBSEVA SA	1 years
William Brown	M	42	OBSEVA SA	1 years
Kristin Strandberg	F	35	SWEDISH ORPHAN BIOVITRUM AB	-
Olav Hellebø	M	59	WEIFA ASA	3 years
Sven Håkan Björklund	M	68	SWEDISH ORPHAN BIOVITRUM AB	7 years
William Louv	M	-	GSK PLC	21 years
David S. Schilansky	M	48	LYSOGENE	6 years
Cameron McDonough	M	53	SWEDISH ORPHAN BIOVITRUM AB	6 years
Hilde Hermansen Steineger	M	58	WEIFA ASA	6 years
Anthony David Sedgwick	M	68	SILENCE THERAPEUTICS PLC	2 years
Robert Spiegel	M	73	WEIFA ASA	-
Hilde Furberg	F	65	WEIFA ASA	1 years
Stephanie Burns	M	69	GSK PLC	9 years
Johannes G. C. P. Schikan	M	66	SWEDISH ORPHAN BIOVITRUM AB	9 years
Patrick J. T. Vallance	M	64	GSK PLC	-
Thomas Kudsk Larsen	M	50	SWEDISH ORPHAN BIOVITRUM AB	2 years
Theresa Heggie	F	63	SWEDISH ORPHAN BIOVITRUM AB	1 years
Olivier Danos	M	66	LYSOGENE	9 years
Barbara A. Ruskin	M	-	SILENCE THERAPEUTICS PLC	-
David Allsop	M	-	SWEDISH ORPHAN BIOVITRUM AB	-
Andrew Humberstone	M	-	OBSEVA SA	-
Philippe Pierre Goupit	M	-	LYSOGENE	-
Lena Elisabeth Svanberg	M	63	SWEDISH ORPHAN BIOVITRUM AB	-
Murray Stewart	M	63	GSK PLC	17 years
Catarina Edfjäll	M	59	OBSEVA SA	3 years
Roy Anderson	M	76	GSK PLC	11 years
Daniel Podolsky	M	70	GSK PLC	10 years
Philip Haworth	M	68	SILENCE THERAPEUTICS PLC	1 years
Michèle Barzach	M	-	GSK PLC	7 years
Maxine Gowen	M	66	GSK PLC	13 years
Barbara Duncan	F	59	OBSEVA SA	5 years
Jean-Pierre Garnier	M	75	GSK PLC	8 years
H. Culp	M	60	GSK PLC	9 years
Jeremy Curnock-Cook	M	75	SILENCE THERAPEUTICS PLC	-
Robert P. Roche	M	68	GSK PLC	-
James Healy	M	58	OBSEVA SA	8 years
Deryck Charles Maughan	M	76	GSK PLC	12 years
Anders Paul Wiklund	M	84	WEIFA ASA	3 years
Ian Maurice Gray Prosser	M	81	GSK PLC	9 years
Robert Wilson	M	81	GSK PLC	11 years
Christopher Gent	M	75	GSK PLC	11 years
Richard Sykes	M	79	GSK PLC	7 years
Crispin Davis	M	75	GSK PLC	10 years
Peter Traber	M	69	GSK PLC	3 years
Tom de Swaan	M	78	GSK PLC	9 years
Iain Ross	M	71	SILENCE THERAPEUTICS PLC	6 years
John Melvyn Davies	M	68	SILENCE THERAPEUTICS PLC	14 years
Jeremy Randall	M	60	SILENCE THERAPEUTICS PLC	5 years
Thomas Christély	M	-	SILENCE THERAPEUTICS PLC	-
Alex Howarth	M	55	GSK PLC	10 years
Ed Mathers Mathers	M	64	OBSEVA SA	8 years
Julian Heslop	M	70	GSK PLC	13 years
Christopher Viehbacher	M	64	GSK PLC	20 years
Brian O'Callaghan	M	54	OBSEVA SA	3 years
Paula Treutiger	F	57	SWEDISH ORPHAN BIOVITRUM AB	3 years
Max Herrmann	M	-	SILENCE THERAPEUTICS PLC	2 years
Stina Margareta Gestrelius	M	75	WEIFA ASA	-
Robert Carr	M	-	GSK PLC	26 years

Statistics

Country	Connections	% of total
United Kingdom	37	37.00%
Sweden	26	26.00%
France	20	20.00%
Switzerland	12	12.00%
Norway	7	7.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections